BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8470 related articles for article (PubMed ID: 2454612)

  • 1. [BRM in the treatment of cancer].
    Takaku F
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-3):1597-602. PubMed ID: 2454612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical evaluation of BRMs in gastric cancer patients].
    Ochiai T; Isono K
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-3):1609-14. PubMed ID: 2968070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future perspectives for biological response modifiers: a viewpoint.
    Mihich E
    Semin Oncol; 1986 Jun; 13(2):234-54. PubMed ID: 2424090
    [No Abstract]   [Full Text] [Related]  

  • 4. Current status of melanoma treatment with interferon, cytokines and other biologic response modifiers in Japan.
    Ishihara K; Hayasaka K; Yamazaki N
    J Invest Dermatol; 1989 May; 92(5 Suppl):326S-328s. PubMed ID: 2469742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological response modifiers: preclinical evaluation and clinical activity.
    Smalley RV; Oldham RK
    Crit Rev Oncol Hematol; 1984; 1(3):259-94. PubMed ID: 6085037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Present state and perspective of cytokine research].
    Takaku F
    Hum Cell; 1993 Jun; 6(2):75-81. PubMed ID: 7692952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of interferons in the treatment of malignant neoplasms.
    Murren JR; Buzaid AC
    Yale J Biol Med; 1989; 62(3):271-90. PubMed ID: 2479178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic therapy of melanoma with cytokines and lymphocytes.
    Bear HD; Hamad GG; Kostuchenko PJ
    Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [General concept of immunomodulators].
    Nihon Rinsho; 1990 Aug; 48 Suppl():880-935. PubMed ID: 1700171
    [No Abstract]   [Full Text] [Related]  

  • 10. Biological response modifiers.
    Oldham RK
    J Natl Cancer Inst; 1983 May; 70(5):789-96. PubMed ID: 6188871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biologic response modifiers in the treatment of solid tumors].
    Tagliaferri F; Lucandri G; Stipa F; Stipa S
    Recenti Prog Med; 1991 Jun; 82(6):352-8. PubMed ID: 1718019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Possibilities and limits of the use of interferons in the clinic].
    Ludwig CU
    Schweiz Med Wochenschr; 1989 Nov; 119(44):1539-43. PubMed ID: 2479977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent trends in cancer treatment using cytokines].
    Urushizaki I
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):897-905. PubMed ID: 2471455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological Response Modifiers Programme and cancer chemotherapy.
    Oldham RK
    Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytokine treatment of renal cell carcinoma].
    Tazaki H
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):29-36. PubMed ID: 8291913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologicals and biological response modifiers: fourth modality of cancer treatment.
    Oldham RK
    Cancer Treat Rep; 1984 Jan; 68(1):221-32. PubMed ID: 6198081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical application of anticancer cytokines].
    Watanabe N
    Nihon Rinsho; 1992 Aug; 50(8):1973-7. PubMed ID: 1279241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 424.